Skip to main content
Premium Trial:

Request an Annual Quote

Isis, CHDI to Use KineMed Biomarker Platform in Huntington's Disease Effort

Premium

Diagnostic biomarker firm KineMed said this week that it has signed a deal to provide its translational biomarker platform to Isis Pharmaceuticals and CHDI Foundation for use in their partnership developing an antisense-based treatment for Huntington's disease.

"A pharmacodynamic biomarker could be an important contribution to our clinical development efforts,” Frank Bennett, senior vice president of research at Isis, said in a statement.

Specific terms of the arrangement were not disclosed.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.